Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 30,385 shares of Class A Common Stock for a weighted average price of $3.58 per share.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage for Clover Health Investments, Corp. (CLOV), reported the sale of 30,385 shares of Class A Common Stock.
• The transaction occurred on November 4, 2025, at a weighted average price of $3.58 per share.
• The shares were sold in multiple transactions with prices ranging from $3.49 to $3.67, inclusive.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Reynoso on March 13, 2025.
• Following this transaction, Mr. Reynoso beneficially owns 2,793,411 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: The sale by a key executive, while executed under a pre-arranged 10b5-1 plan, is a neutral event from a compliance perspective but can be interpreted with slight caution by the market as it reduces insider ownership.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to immediate non-public information, which is a positive for corporate governance and transparency.

Negatives

• A key executive reducing their stake, even if pre-planned, can be perceived by the market as a lack of confidence or a signal that the stock may not have significant upside in the near term.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it solely reports an insider transaction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape within the healthcare or Medicare Advantage sectors.

Corporate Governance

Stakeholder Impact

• Shareholders may view the reduction in a key executive's stake with caution, potentially leading to questions about management's long-term conviction, although the 10b5-1 plan mitigates immediate concerns about opportunistic selling.

Key Dates

Recommendation

A single insider sale, even by a key executive, when executed under a pre-arranged 10b5-1 plan, does not typically warrant a strong buy or sell recommendation. It's a data point that suggests a neutral stance, prompting investors to monitor future insider activity and company performance.

Keywords

Clover Health, CLOV, Insider Trading, Form 4, Stock Sale, Jamie L. Reynoso, 10b5-1 Plan, Medicare Advantage, CEO